RCT: In patients with rheumatoid arthritis, treatment with oral drug Tofacitinib increases cardiovascular and cancer risk compared to treatment with subcutaneous TNF inhibitors.

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)

Video: CV and Cancer Risk with Tofacitinib in RA – New England Journal of Medicine

Commentary: CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis – HealthDay